FDA label 7e1cca56-d737-4916-a4a9-10cd8bbc0c01
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- SPL set ID
- 7e1cca56-d737-4916-a4a9-10cd8bbc0c01
- SPL ID
- 7e1cca56-d737-4916-a4a9-10cd8bbc0c01
- Version
- 1
- Effective date
- 2026-08-31
- Source export date
- 2026-11-13
- Source partition
- 3
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0003-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/2df682709a18af7b632162dce4573ac151d74d432118e70b8675083d83b89813/drug-label-0003-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 15:47:30
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| spl id | 7e1cca56-d737-4916-a4a9-10cd8bbc0c01 | id | |
| spl set id | 7e1cca56-d737-4916-a4a9-10cd8bbc0c01 | set_id |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING: SEVERE BLEEDING AND THROMBOSIS COMPLICATIONS • THROMBIN-JMI ® LIQUID can cause fatal severe bleeding or thrombosis. Thrombosis may result from the development of antibodies against bovine thrombin. Bleeding may result from the development of antibodies against factor V. These may cross-react with human factor V and lead to its deficiency. ( 5.2 , 5.3 ) • Do not re-expose patients to THROMBIN-JMI LIQUID if there are known or suspected antibodies to bovine thrombin and/or factor V. ( 4 , 5.3 ) • Monitor patients for abnormal coagulation laboratory values, bleeding, or thrombosis. ( 5.3 ) WARNING: SEVERE BLEEDING AND THROMBOSIS COMPLICATIONS See full prescribing information for complete boxed warning • THROMBIN-JMI ® LIQUID can cause fatal severe bleeding or thrombosis. Thrombosis may result from the development of antibodies against bovine thrombin. Bleeding may result from the development of antibodies against factor V. These may cross-react with human factor V and lead to its deficiency. ( 5.2 , 5.3 ) • Do not re-expose patients to THROMBIN-JMI LIQUID if there are known or suspected antibodies to bovine thrombin and/or factor V. ( 4 , 5.3 ) • Monitor patients for abnormal coagulation laboratory values, bleeding, or thrombosis. ( 5.3 )
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings and cautions
5 WARNINGS AND PRECAUTIONS • Allergic reactions, including anaphylactic/anaphylactoid reactions, have been reported following administration of THROMBIN-JMI LIQUID. ( 5.1 ) • Institute intensive supportive measures and treat individual symptoms. Secure the airway and establish adequate respiratory exchange. ( 5.1 ) • THROMBIN-JMI LIQUID causes thrombosis if it enters the circulatory system. Apply topically. DO NOT INJECT. ( 5.2 ) • Inhibitory antibodies may develop in patients and interfere with hemostasis. Monitor patients for abnormal coagulation laboratory values, bleeding, or thrombosis. ( 5.3 ) 5.1 Hypersensitivity Reactions • Allergic reactions, including anaphylactic/anaphylactoid reactions, have been reported following administration of THROMBIN-JMI LIQUID. • Institute intensive supportive measures and treat individual symptoms. Secure the airway and establish adequate respiratory exchange. 5.2 Thrombosis THROMBIN-JMI LIQUID causes thrombosis if it enters the circulatory system due to its action in the clotting system. Apply topically. DO NOT INJECT. 5.3 Immunogenicity Inhibitory antibodies may develop in patients and interfere with hemostasis. Do not re-expose patients to THROMBIN-JMI LIQUID if there are known or suspected antibodies to bovine thrombin and/or factor V, due to the potential for these antibodies to interfere with hemostasis. Monitor patients for abnormal coagulation laboratory values, bleeding, or thrombosis. Bleeding Bleeding may result from the development of antibodies against factor V. These antibodies may cross-react with human factor V and lead to human factor V deficiency. Thrombosis Thrombosis may result from the development of antibodies against bovine thrombin.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The most common adverse reactions (incidence greater than or equal to 2%) following administration of THROMBIN-JMI were: hypersensitivity, bleeding, anemia, post-operative wound infection, thromboembolic events, hypotension, pyrexia, tachycardia and thrombocytopenia. Most common adverse reactions (incidence ≥ 2%) are hypersensitivity, bleeding, anemia, post-operative wound infection, thromboembolic events, hypotension, pyrexia, tachycardia and thrombocytopenia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety assessment of THROMBIN-JMI LIQUID is based primarily on the review of post marketing publications summarizing four (4) randomized controlled clinical trials in which THROMBIN-JMI was used as a comparator 2–5 , and one (1) observational study 6 [see Clinical Studies (14) ] . Study 1 In a randomized, double-blinded, controlled trial that compared recombinant human thrombin to THROMBIN-JMI, 206 patients received THROMBIN-JMI and 205 patients received recombinant human thrombin as adjuncts to hemostasis in liver resection, spine, peripheral arterial bypass, and dialysis access surgeries. 2 Four hundred one (401) patients completed the trial. The reported adverse reactions in both treatment groups were: cardiac events (18%), hypersensitivity (17%), other infections (15%), bleeding (11%), postoperative wound infection (10%), and thromboembolic events (5%). Among 200 patients who were evaluated for the presence of antibodies to THROMBIN-JMI, 10 patients (5%) were positive at baseline and 43 (21.5%) after treatment. The seroconversion rate in THROMBIN-JMI group was 18.4%. Study 2 In a multicenter, prospective, randomized, double-blinded, controlled trial that compared plasma-derived human thrombin to THROMBIN-JMI, 152 patients received THROMBIN-JMI and 153 patients received human thrombin applied topically to the target bleeding site with a gelatin sponge. 3 Serious adverse reactions (pyrexia and post-procedural hematoma) were reported in two patients receiving THROMBIN-JMI. In this study, 16 out of 126 (12.7%) patients who received THROMBIN-JMI demonstrated seroconversion for at least one of the four antibodies assayed. The four separate ELISA assays used to detect development of antibodies and the corresponding antibody development rates included: 1) Anti-bovine thrombin 10/126 (7.94%), 2) Anti-bovine factor V/Va 12/126 (9.52%), 3) Anti-human thrombin 3/126 (2.38%) and 4) Anti-human factor V/Va 0/126 (0%). Study 3 The effect of repeat exposure was evaluated in a multi-center, prospective, randomized, double-blinded, controlled trial on 72 patients with diabetic foot ulcers, using a gel prepared with THROMBIN-JMI and autologous platelet rich plasma that was applied weekly for 12 weeks. 4 Forty (40) patients were treated with the gel at fourteen (14) sites. Safety parameters were evaluated during the 12 weeks of treatment and the three-month follow-up period. No serious adverse reactions related to the gel treatment were reported. Study 4 In a prospective, randomized, phase 2, non-inferiority study, topical human thrombin was compared with THROMBIN-JMI during vascular, hepatic, soft tissue, and spinal open surgery procedures. 5 A total of 205 patients were randomized in a 2:1 ratio to receive human thrombin (n=137) or THROMBIN-JMI (n=68). The most common treatment-emergent adverse reactions (experienced by >5% patients within a treatment group) were procedural pain, nausea, constipation, pruritus, muscle spasms, insomnia, pyrexia, and vomiting. Two patients in the THROMBIN-JMI group (3.2% of treated patients) showed low-level titers of antibodies to bovine factor V. 6.2 Postmarketing Experience The following serious adverse reactions have been identified during post approval use of THROMBIN-JMI: anaphylactic reactions, prolonged prothrombin time, prolonged activated partial thromboplastin time, disseminated intravascular coagulation, factor V deficiency, post-procedural hematoma, swelling and Staphylococcal wound infection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.